Tempus AI acquires Personalis for $1.5 billion to expand cancer screening and MRD capabilities

Tempus AI has announced its acquisition of cancer test maker Personalis in a deal valued at $1.5 billion, marking a significant expansion of the company's cancer screening capabilities and AI-enabled precision medicine offerings 1

1

. The transaction will be funded primarily through Tempus stock, though the company retains the option to use cash for up to 50% of the consideration 2

2

. Personalis shareholders will receive $16.25 per share, representing a 6% premium to the company's Friday closing price and a 28% premium to the unaffected 30-day volume-weighted average price 1

1

.

Strategic Focus on Minimal Residual Disease Market

The Personalis acquisition positions Tempus AI to capture what the company describes as a $20 billion opportunity in the minimal residual disease market 1

1

. Through this deal, Tempus will gain access to Personalis' NeXT Personal platform, a cancer test designed to detect microscopic traces of tumor DNA in a patient's blood to monitor treatment response and identify early recurrence 3

3

. Eric Lefkofsky, CEO of Tempus AI, emphasized the strategic value of combining Personalis' highly sensitive MRD technology with Tempus' AI and data platform to improve cancer patient monitoring and treatment outcomes 1

1

.

Building on Existing Partnership

This acquisition builds on an existing collaboration between the two companies that began in November 2023, when Tempus invested in Personalis to develop the NeXT Personal test 3

3

. According to Lefkofsky, the partnership had already demonstrated the strength of combining MRD technology with Tempus' commercial infrastructure, and with clinical adoption and reimbursement momentum building, the companies are well positioned to capture the market opportunity . Chris Hall, CEO of Personalis (PSNL), expressed confidence that the combined capabilities and resources will accelerate innovation in cancer genomics and deliver value to patients and shareholders 1

1

.

Market Reaction and Deal Structure

Markets greeted the announcement cautiously, with Tempus AI shares falling 8.06% to $48.24 and Personalis shares declining 5% in premarket trading 1

1

3

3

. Several analysts attributed the negative reaction to the stock acquisition structure, which dilutes existing shareholders 2

2

. The transaction is expected to close in late 2026 or early 2027, giving both companies time to integrate operations and align their AI-driven cancer screening solutions 1

1

.

Financial Position and Outlook

Tempus AI held $521.17 million in cash and cash equivalents as of March 31, 2026, providing financial flexibility for the deal 1

1

. The company is scheduled to report earnings on July 30, 2026, with analysts expecting a loss of 20 cents per share, narrowing from 22 cents a year earlier, and revenue of $380.24 million, up from $314.63 million 1

1

. Despite the stock decline, Tempus AI carries a Buy rating with an average analyst price forecast of $66.82, suggesting confidence in the company's long-term precision medicine strategy and expanded oncology portfolio 1

1

. Tempus believes the NeXT Personal business is now mature enough to offer strong profitability potential as the company bolsters its ambitions in artificial intelligence solutions applied to cancer treatment 2

2

.